Imaging in Suspected Renal-Cell Carcinoma: Systematic Review.


Journal

Clinical genitourinary cancer
ISSN: 1938-0682
Titre abrégé: Clin Genitourin Cancer
Pays: United States
ID NLM: 101260955

Informations de publication

Date de publication:
04 2019
Historique:
received: 08 11 2017
revised: 08 07 2018
accepted: 30 07 2018
pubmed: 12 12 2018
medline: 25 2 2020
entrez: 12 12 2018
Statut: ppublish

Résumé

To systematically assessed the diagnostic performance of contrast-enhanced computed tomography (CT) compared to other imaging modalities for diagnosing and staging renal-cell carcinoma in adults. A comprehensive literature search was conducted through various electronic databases. Data from the selected studies were extracted and pooled, and median sensitivity and specificity were calculated wherever possible. Forty studies analyzing data of 4354 patients were included. They examined CT, magnetic resonance imaging (MRI), positron emission tomography-CT, and ultrasound (US). For CT, median sensitivity and specificity were 88% (interquartile range [IQR] 81%-94%) and 75% (IQR 51%-90%), and for MRI they were 87.5% (IQR 75.25%-100%) and 89% (IQR 75%-96%). Staging sensitivity and specificity for CT were 87% and 74.5%, while MRI showed a median sensitivity of 90% and specificity of 75%. For US, the results varied greatly depending on the corresponding technique. Contrast-enhanced US had a median diagnostic sensitivity of 93% (IQR 88.75%-98.25%) combined with mediocre specificity. The diagnostic performance of unenhanced US was poor. For positron emission tomography-CT, diagnostic accuracy values were good but were based on only a small amount of data. Limitations include the strong heterogeneity of data due to the large variety in imaging techniques and tumor histotypes. Contrast-enhanced CT and MRI remain the diagnostic mainstay for renal-cell carcinoma, with almost equally high diagnostic and staging accuracy. For specific questions, a combination of different imaging techniques such as CT or MRI and contrast-enhanced US may be useful. There is a need for future large prospective studies to further increase the quality of evidence.

Identifiants

pubmed: 30528378
pii: S1558-7673(18)30338-0
doi: 10.1016/j.clgc.2018.07.024
pii:
doi:

Substances chimiques

Contrast Media 0

Types de publication

Comparative Study Journal Article Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

e345-e355

Informations de copyright

Copyright © 2018 Elsevier Inc. All rights reserved.

Auteurs

Christina Vogel (C)

Department of Urology, Ludwig-Maximilians University, Munich, Germany.

Brigitte Ziegelmüller (B)

Department of Urology, Ludwig-Maximilians University, Munich, Germany.

Börje Ljungberg (B)

Department of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University, Umeå, Sweden.

Karim Bensalah (K)

Department of Urology, University of Rennes, Rennes, France.

Axel Bex (A)

Department of Urology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.

Steven Canfield (S)

Division of Urology, University of Texas Medical School at Houston, Houston, TX.

Rachel H Giles (RH)

Patient Advocate International Kidney Cancer Coalition (IKCC), Duivendrecht, The Netherlands.

Milan Hora (M)

Department of Urology, Faculty Hospital and Faculty of Medicine in Pilsen, Charles University in Prague, Prague, Czech Republic.

Markus A Kuczyk (MA)

Department of Urology and Urologic Oncology, Hannover Medical School, Hannover, Germany.

Axel S Merseburger (AS)

Department of Urology, University Hospital Schleswig-Holstein, Lübeck, Germany.

Thomas Powles (T)

The Royal Free NHS Trust and Barts Cancer Institute, Queen Mary University of London, London, UK.

Laurence Albiges (L)

Department of Cancer Medicine, Institut Gustave Roussy, Villejuif, France.

Fiona Stewart (F)

Academic Urology Unit, University of Aberdeen, Aberdeen, UK.

Allseandro Volpe (A)

Division of Urology, Maggiore della Carità Hospital, University of Eastern Piedmont, Novara, Italy.

Anno Graser (A)

Institute of Radiology, Ludwig-Maximilians University, Munich, Germany.

Marcus Schlemmer (M)

Department of Oncology, Ludwig-Maximilians University, Munich, Germany.

C Yuan (C)

Academic Urology Unit, University of Aberdeen, Aberdeen, UK.

Thomas Lam (T)

Academic Urology Unit, University of Aberdeen, Aberdeen, UK; Department of Urology, Aberdeen Royal Infirmary, Aberdeen, UK.

Michael Staehler (M)

Department of Urology, Ludwig-Maximilians University, Munich, Germany. Electronic address: michael.staehler@med.uni-muenchen.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH